Table 5.
Selected SNP hazard ratios of death from head and neck cancer, stratified by summary AJCC stagea (models and covariates as in Table 5).
| Stage I (n = 279) |
Stage II/III (n=431) |
Stage IV (n = 517) |
||||||
|---|---|---|---|---|---|---|---|---|
| Gene | SNP | Major/minor alleles |
# Cases: major/ any minor |
HR (95% CI)b | # Cases: major/ Any minor |
HR (95% CI)b | # Cases: major/ Any minor |
HR (95% CI)b |
| CYP2E1 | rs3813865 | G/C | 251/28 | – | 382/49 | 2.80(1.45–5.44) | 469/48 | 2.18 (1.23–3.88) |
| rs8192772 | T/C | 240/39 | 1.47 (0.38–5.69) | 358/73 | 1.89 (1.10–3.26) | 428/88 | 1.40 (0.90–2.18) | |
| rs7092584 | C/T | 227/52 | 0.95 (0.25–3.67) | 337/93 | 1.77 (1.06–2.96) | 398/118 | 0.97 (0.64–1.47) | |
| rs743535 | C/T | 227/51 | 1.70 (0.50–5.80) | 340/87 | 1.52 (0.88–2.60) | 402/111 | 1.29 (0.86–1.94) | |
| rs2249695 | C/T | 156/123 | 0.73 (0.22–2.37) | 217/213 | 1.48 (0.89–2.46) | 250/267 | 1.25 (0.84–1.88) | |
| GPx2 | rs11623705 | G/T | 229/50 | 1.49 (0.43–5.10) | 348/83 | 1.78 (1.04–3.05) | 423/94 | 1.31 (0.84–2.06) |
| rs2412065 | G/C | 163/116 | 1.25 (0.41–3.83) | 245/186 | 1.32 (0.82–2.13) | 290/227 | 1.32 (0.91–1.92) | |
| SOD1 | rs10432782 | T/G | 211/68 | 1.05 (0.31–3.53) | 297/133 | 1.54 (0.95–2.47) | 368/149 | 0.98 (0.66–1.46) |
| rs2070424 | A/G | 240/39 | 0.35 (0.04–2.85) | 342/89 | 1.81 (1.08–3.04) | 423/94 | 1.10 (0.69–1.76) | |
| SOD2 | rs2842980 | A/T | 174/105 | 1.67 (0.59–4.72) | 245/186 | 1.77 (1.11–2.83) | 298/219 | 1.40 (0.97–2.03) |
SNPs were selected for presentation in this table if the confidence interval for the adjusted HR and the Kaplan–Meier log-rank p-value both appeared to depart from the null, for either all-cause or cancer-specific death, or both.
Cox models used to calculate hazard ratios for head and neck cancer-specific death included SNP coded for dominant model (any minor allele versus homozygous major allele), age, sex, race, anatomical site, T stage, N stage, M stage, angiolymphatic invasion status, surgical treatment, chemotherapy treatment, radiation treatment, presence of comorbid cardiovascular or lung disease, presence of comorbid liver disease or hepatitis, duration of smoking cigarettes (years), ever exposure to environmental tobacco smoke at work, reception of at least one routine dental visit in past 10 years, ever loss of a tooth due to disease, federal poverty level. 25 datasets were imputed, and results were summarized as a single HR.